Protective efficacy of a bivalent inactivated reassortant H1N1 influenza virus vaccine against European avian-like and classical swine influenza H1N1 viruses in mice

Ruan, Banpu; Yao, Yun; Wang, Shuai-Yong; Gong, Xiaoyi; Liu, Xiaomin; Wang, Qi; Yu, Lingxue; Zhu, Shi-Qiang; Wang, Juan; Shan, Tongling; Zhou, Yanjun; Wu, Tong; Zheng, Hao; Li, Guoxin; Gao, Fei; Kong, Ning; Yu, Hai; Tong, Guangzhi

doi:10.1016/j.vetmic.2020.108724

Cited by 2 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After the challenge, the weight changes of the mice were recorded for 14 days. According to previous studies, mice showing >25% of their initial body weight loss were defined as an end-point and were euthanized [49,50]. In this study, two mice died in the PBS-group challenge with the H1N1 virus, and three mice lost more than 25% of their initial body weight during the observation period.…”

Section: Discussionmentioning

confidence: 99%

Nanoparticle-Based Bivalent Swine Influenza Virus Vaccine Induces Enhanced Immunity and Effective Protection against Drifted H1N1 and H3N2 Viruses in Mice

Tang

Cui

Chang

et al. 2022

Viruses

View full text Add to dashboard Cite

Swine influenza virus (SIV) circulates worldwide, posing substantial economic loss and disease burden to humans and animals. Vaccination remains the most effective way to prevent SIV infection and transmission. In this study, we evaluated the protective efficacy of a recombinant, baculovirus-insect cell system-expressed bivalent nanoparticle SIV vaccine in mice challenged with drifted swine influenza H1N1 and H3N2 viruses. After a prime-boost immunization, the bivalent nanoparticle vaccine (BNV) induced high levels of hemagglutination inhibition (HAI) antibodies, virus-neutralization (VN) antibodies, and antigen-specific IgG antibodies in mice, as well as more efficient cytokine levels. The MF59 and CPG1 adjuvant could significantly promote both humoral and cellular immunity of BNV. The MF59 adjuvant showed a balanced Th1/Th2 immune response, and the CPG1 adjuvant tended to show a Th1-favored response. The BALB/c challenge test showed that BNV could significantly reduce lung viral loads and feces viral shedding, and showed fewer lung pathological lesions than those in PBS and inactivated vaccine groups. These results suggest that this novel bivalent nanoparticle swine influenza vaccine can be used as an efficacious vaccine candidate to induce robust immunity and provide broad protection against drifted subtypes in mice. Immune efficacy in pigs needs to be further evaluated.

show abstract

Section: Discussionmentioning

confidence: 99%